Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Longitudinal analysis of group A Streptococcus emm types and emm clusters in a high prevalence setting reveals past infection does not prevent future infection.

Campbell PT, Tong SYC, Geard N, Davies MR, Worthing KA, Lacey JA, Smeesters PR, Batzloff MR, Kado J, Jenney AWJ, McVernon J, Steer AC.

J Infect Dis. 2019 Nov 21. pii: jiz615. doi: 10.1093/infdis/jiz615. [Epub ahead of print]

PMID:
31748786
2.

Controlled human infection for vaccination against Streptococcus pyogenes (CHIVAS): Establishing a group A Streptococcus pharyngitis human infection study.

Osowicki J, Azzopardi KI, Baker C, Waddington CS, Pandey M, Schuster T, Grobler A, Cheng AC, Pollard AJ, McCarthy JS, Good MF, Walker MJ, Dale JB, Batzloff MR, Carapetis JR, Smeesters PR, Steer AC.

Vaccine. 2019 Jun 6;37(26):3485-3494. doi: 10.1016/j.vaccine.2019.03.059. Epub 2019 May 14.

PMID:
31101422
3.

An Experimental Group A Streptococcus Vaccine That Reduces Pharyngitis and Tonsillitis in a Nonhuman Primate Model.

Rivera-Hernandez T, Carnathan DG, Jones S, Cork AJ, Davies MR, Moyle PM, Toth I, Batzloff MR, McCarthy J, Nizet V, Goldblatt D, Silvestri G, Walker MJ.

mBio. 2019 Apr 30;10(2). pii: e00693-19. doi: 10.1128/mBio.00693-19.

4.

Polyglutamic acid-trimethyl chitosan-based intranasal peptide nano-vaccine induces potent immune responses against group A streptococcus.

Nevagi RJ, Khalil ZG, Hussein WM, Powell J, Batzloff MR, Capon RJ, Good MF, Skwarczynski M, Toth I.

Acta Biomater. 2018 Oct 15;80:278-287. doi: 10.1016/j.actbio.2018.09.037. Epub 2018 Sep 25.

PMID:
30266637
5.

Evaluation of safety and immunogenicity of a group A streptococcus vaccine candidate (MJ8VAX) in a randomized clinical trial.

Sekuloski S, Batzloff MR, Griffin P, Parsonage W, Elliott S, Hartas J, O'Rourke P, Marquart L, Pandey M, Rubin FA, Carapetis J, McCarthy J, Good MF.

PLoS One. 2018 Jul 2;13(7):e0198658. doi: 10.1371/journal.pone.0198658. eCollection 2018.

6.

Skin infection boosts memory B-cells specific for a cryptic vaccine epitope of group A streptococcus and broadens the immune response to enhance vaccine efficacy.

Pandey M, Ozberk V, Langshaw EL, Calcutt A, Powell J, Batzloff MR, Rivera-Hernandez T, Good MF.

NPJ Vaccines. 2018 Apr 26;3:15. doi: 10.1038/s41541-018-0053-9. eCollection 2018.

7.

Induction of immunity following vaccination with a chemically attenuated malaria vaccine correlates with persistent antigenic stimulation.

Reiman JM, Kumar S, Rodriguez IB, Gnidehou S, Ito K, Stanisic DI, Lee M, McPhun V, Majam V, Willemsen NM, Batzloff MR, Raja AI, Dooley B, Hoffman SL, Yanow SK, Good MF.

Clin Transl Immunology. 2018 Apr 11;7(4):e1015. doi: 10.1002/cti2.1015. eCollection 2018.

8.

Physicochemical characterisation, immunogenicity and protective efficacy of a lead streptococcal vaccine: progress towards Phase I trial.

Pandey M, Powell J, Calcutt A, Zaman M, Phillips ZN, Ho MF, Batzloff MR, Good MF.

Sci Rep. 2017 Oct 23;7(1):13786. doi: 10.1038/s41598-017-14157-7.

9.

Enhancing Vaccine Efficacy by Engineering a Complex Synthetic Peptide To Become a Super Immunogen.

Nordström T, Pandey M, Calcutt A, Powell J, Phillips ZN, Yeung G, Giddam AK, Shi Y, Haselhorst T, von Itzstein M, Batzloff MR, Good MF.

J Immunol. 2017 Oct 15;199(8):2794-2802. doi: 10.4049/jimmunol.1700836. Epub 2017 Sep 13.

10.

Comparison of Fluorinated and Nonfluorinated Lipids in Self-Adjuvanting Delivery Systems for Peptide-Based Vaccines.

Hussein WM, Mukaida S, Azmi F, Bartlett S, Olivier C, Batzloff MR, Good MF, Skwarczynski M, Toth I.

ACS Med Chem Lett. 2017 Jan 24;8(2):227-232. doi: 10.1021/acsmedchemlett.6b00453. eCollection 2017 Feb 9.

11.

Synthesis, Characterization and Immunological Evaluation of Self-Adjuvanting Group A Streptococcal Vaccine Candidates Bearing Various Lipidic Adjuvanting Moieties.

Fagan V, Hussein WM, Su M, Giddam AK, Batzloff MR, Good MF, Toth I, Simerska P.

Chembiochem. 2017 Mar 16;18(6):545-553. doi: 10.1002/cbic.201600639. Epub 2017 Feb 15.

PMID:
28075053
12.

Streptococcal Immunity Is Constrained by Lack of Immunological Memory following a Single Episode of Pyoderma.

Pandey M, Ozberk V, Calcutt A, Langshaw E, Powell J, Rivera-Hernandez T, Ho MF, Philips Z, Batzloff MR, Good MF.

PLoS Pathog. 2016 Dec 27;12(12):e1006122. doi: 10.1371/journal.ppat.1006122. eCollection 2016 Dec.

13.

Novel platform technology for modular mucosal vaccine that protects against streptococcus.

Zaman M, Ozberk V, Langshaw EL, McPhun V, Powell JL, Phillips ZN, Ho MF, Calcutt A, Batzloff MR, Toth I, Hill GR, Pandey M, Good MF.

Sci Rep. 2016 Dec 15;6:39274. doi: 10.1038/srep39274.

14.

Double adjuvanting strategy for peptide-based vaccines: trimethyl chitosan nanoparticles for lipopeptide delivery.

Marasini N, Giddam AK, Khalil ZG, Hussein WM, Capon RJ, Batzloff MR, Good MF, Toth I, Skwarczynski M.

Nanomedicine (Lond). 2016 Dec;11(24):3223-3235. Epub 2016 Nov 10.

PMID:
27830630
15.

Lipid core peptide/poly(lactic-co-glycolic acid) as a highly potent intranasal vaccine delivery system against Group A streptococcus.

Marasini N, Khalil ZG, Giddam AK, Ghaffar KA, Hussein WM, Capon RJ, Batzloff MR, Good MF, Skwarczynski M, Toth I.

Int J Pharm. 2016 Nov 20;513(1-2):410-420. doi: 10.1016/j.ijpharm.2016.09.057. Epub 2016 Sep 20.

PMID:
27659862
16.

Linear and branched polyacrylates as a delivery platform for peptide-based vaccines.

Chandrudu S, Bartlett S, Khalil ZG, Jia Z, Hussein WM, Capon RJ, Batzloff MR, Good MF, Monteiro MJ, Skwarczynski M, Toth I.

Ther Deliv. 2016 Sep;7(9):601-9. doi: 10.4155/tde-2016-0037.

PMID:
27582233
17.

Preclinical immunogenicity and safety of a Group A streptococcal M protein-based vaccine candidate.

Batzloff MR, Fane A, Gorton D, Pandey M, Rivera-Hernandez T, Calcutt A, Yeung G, Hartas J, Johnson L, Rush CM, McCarthy J, Ketheesan N, Good MF.

Hum Vaccin Immunother. 2016 Dec;12(12):3089-3096. doi: 10.1080/21645515.2016.1222999. Epub 2016 Aug 19.

18.

The Role of Size in Development of Mucosal Liposome-Lipopeptide Vaccine Candidates Against Group A Streptococcus.

Ghaffar KA, Marasini N, Giddam AK, Batzloff MR, Good MF, Skwarczynski M, Toth I.

Med Chem. 2016;13(1):22-27. doi: 10.2174/1573406412666160720093138.

PMID:
27449794
19.

Highly Immunogenic Trimethyl Chitosan-based Delivery System for Intranasal Lipopeptide Vaccines against Group A Streptococcus.

Marasini N, Ghaffar KA, Giddam AK, Batzloff MR, Good MF, Skwarczynski M, Toth I.

Curr Drug Deliv. 2017;14(5):701-708. doi: 10.2174/1567201813666160721141322.

PMID:
27440071
20.

Burkholderia pseudomallei Rapidly Infects the Brain Stem and Spinal Cord via the Trigeminal Nerve after Intranasal Inoculation.

St John JA, Walkden H, Nazareth L, Beagley KW, Ulett GC, Batzloff MR, Beacham IR, Ekberg JA.

Infect Immun. 2016 Aug 19;84(9):2681-8. doi: 10.1128/IAI.00361-16. Print 2016 Sep.

21.

Differing Efficacies of Lead Group A Streptococcal Vaccine Candidates and Full-Length M Protein in Cutaneous and Invasive Disease Models.

Rivera-Hernandez T, Pandey M, Henningham A, Cole J, Choudhury B, Cork AJ, Gillen CM, Ghaffar KA, West NP, Silvestri G, Good MF, Moyle PM, Toth I, Nizet V, Batzloff MR, Walker MJ.

mBio. 2016 Jun 14;7(3). pii: e00618-16. doi: 10.1128/mBio.00618-16.

22.

Structure-activity relationship of lipid core peptide-based Group A Streptococcus vaccine candidates.

Chan A, Hussein WM, Ghaffar KA, Marasini N, Mostafa A, Eskandari S, Batzloff MR, Good MF, Skwarczynski M, Toth I.

Bioorg Med Chem. 2016 Jul 15;24(14):3095-101. doi: 10.1016/j.bmc.2016.03.063. Epub 2016 Apr 2.

PMID:
27246859
23.

Multilayer engineered nanoliposomes as a novel tool for oral delivery of lipopeptide-based vaccines against group A Streptococcus.

Marasini N, Giddam AK, Ghaffar KA, Batzloff MR, Good MF, Skwarczynski M, Toth I.

Nanomedicine (Lond). 2016 May;11(10):1223-36. doi: 10.2217/nnm.16.36. Epub 2016 Apr 14.

PMID:
27077314
24.

Liposome-based intranasal delivery of lipopeptide vaccine candidates against group A streptococcus.

Ghaffar KA, Marasini N, Giddam AK, Batzloff MR, Good MF, Skwarczynski M, Toth I.

Acta Biomater. 2016 Sep 1;41:161-8. doi: 10.1016/j.actbio.2016.04.012. Epub 2016 Apr 7.

PMID:
27063491
25.

Combinatorial Synthetic Peptide Vaccine Strategy Protects against Hypervirulent CovR/S Mutant Streptococci.

Pandey M, Mortensen R, Calcutt A, Powell J, Batzloff MR, Dietrich J, Good MF.

J Immunol. 2016 Apr 15;196(8):3364-74. doi: 10.4049/jimmunol.1501994. Epub 2016 Mar 11.

26.

Current Approaches to Group A Streptococcal Vaccine Development.

Dale JB, Batzloff MR, Cleary PP, Courtney HS, Good MF, Grandi G, Halperin S, Margarit IY, McNeil S, Pandey M, Smeesters PR, Steer AC.

In: Ferretti JJ, Stevens DL, Fischetti VA, editors. Streptococcus pyogenes : Basic Biology to Clinical Manifestations [Internet]. Oklahoma City (OK): University of Oklahoma Health Sciences Center; 2016-.
2016 Feb 10.

27.

Plasmodium berghei bio-burden correlates with parasite lactate dehydrogenase: application to murine Plasmodium diagnostics.

De SL, Stanisic DI, Rivera F, Batzloff MR, Engwerda C, Good MF.

Malar J. 2016 Jan 4;15:3. doi: 10.1186/s12936-015-1027-2.

28.

Strategic development of the conserved region of the M protein and other candidates as vaccines to prevent infection with group A streptococci.

Good MF, Pandey M, Batzloff MR, Tyrrell GJ.

Expert Rev Vaccines. 2015;14(11):1459-70. doi: 10.1586/14760584.2015.1081817. Review.

PMID:
26485214
29.

A synthetic M protein peptide synergizes with a CXC chemokine protease to induce vaccine-mediated protection against virulent streptococcal pyoderma and bacteremia.

Pandey M, Langshaw E, Hartas J, Lam A, Batzloff MR, Good MF.

J Immunol. 2015 Jun 15;194(12):5915-25. doi: 10.4049/jimmunol.1500157. Epub 2015 May 15.

30.

Development of cultured Plasmodium falciparum blood-stage malaria cell banks for early phase in vivo clinical trial assessment of anti-malaria drugs and vaccines.

Stanisic DI, Liu XQ, De SL, Batzloff MR, Forbes T, Davis CB, Sekuloski S, Chavchich M, Chung W, Trenholme K, McCarthy JS, Li T, Sim BK, Hoffman SL, Good MF.

Malar J. 2015 Apr 7;14:143. doi: 10.1186/s12936-015-0663-x.

31.

Group A Streptococcal vaccine candidate: contribution of epitope to size, antigen presenting cell interaction and immunogenicity.

Zaman M, Chandrudu S, Giddam AK, Reiman J, Skwarczynski M, McPhun V, Moyle PM, Batzloff MR, Good MF, Toth I.

Nanomedicine (Lond). 2014 Dec;9(17):2613-24. doi: 10.2217/nnm.14.190.

PMID:
25529566
32.

Self-adjuvanting vaccine against group A streptococcus: application of fibrillized peptide and immunostimulatory lipid as adjuvant.

Azmi F, Ahmad Fuaad AA, Giddam AK, Batzloff MR, Good MF, Skwarczynski M, Toth I.

Bioorg Med Chem. 2014 Nov 15;22(22):6401-8. doi: 10.1016/j.bmc.2014.09.042. Epub 2014 Sep 26.

PMID:
25438764
33.

Site-specific incorporation of three toll-like receptor 2 targeting adjuvants into semisynthetic, molecularly defined nanoparticles: application to group a streptococcal vaccines.

Moyle PM, Dai W, Zhang Y, Batzloff MR, Good MF, Toth I.

Bioconjug Chem. 2014 May 21;25(5):965-78. doi: 10.1021/bc500108b. Epub 2014 Apr 18.

PMID:
24712905
34.

Microbially synthesized modular virus-like particles and capsomeres displaying group A streptococcus hypervariable antigenic determinants.

Chuan YP, Wibowo N, Connors NK, Wu Y, Hughes FK, Batzloff MR, Lua LH, Middelberg AP.

Biotechnol Bioeng. 2014 Jun;111(6):1062-70. doi: 10.1002/bit.25172. Epub 2013 Dec 28.

PMID:
24338691
35.

Structure-informed design of an enzymatically inactive vaccine component for group A Streptococcus.

Henningham A, Ericsson DJ, Langer K, Casey LW, Jovcevski B, Chhatwal GS, Aquilina JA, Batzloff MR, Kobe B, Walker MJ.

mBio. 2013 Aug 6;4(4). pii: e00509-13. doi: 10.1128/mBio.00509-13.

36.

Cross-species malaria immunity induced by chemically attenuated parasites.

Good MF, Reiman JM, Rodriguez IB, Ito K, Yanow SK, El-Deeb IM, Batzloff MR, Stanisic DI, Engwerda C, Spithill T, Hoffman SL, Lee M, McPhun V.

J Clin Invest. 2013 Jul 1. pii: 66634. doi: 10.1172/JCI66634. [Epub ahead of print]

37.

Strategies in the development of vaccines to prevent infections with group A streptococcus.

Good MF, Batzloff MR, Pandey M.

Hum Vaccin Immunother. 2013 Nov;9(11):2393-7. Epub 2013 Jun 28. Review.

38.

Polymer-peptide hybrids as a highly immunogenic single-dose nanovaccine.

Ahmad Fuaad AA, Jia Z, Zaman M, Hartas J, Ziora ZM, Lin IC, Moyle PM, Batzloff MR, Good MF, Monteiro MJ, Skwarczynski M, Toth I.

Nanomedicine (Lond). 2014 Jan;9(1):35-43. doi: 10.2217/nnm.13.7. Epub 2013 Apr 23.

PMID:
23611619
39.

An efficient, chemically-defined semisynthetic lipid-adjuvanted nanoparticulate vaccine development system.

Moyle PM, Hartas J, Henningham A, Batzloff MR, Good MF, Toth I.

Nanomedicine. 2013 Oct;9(7):935-44. doi: 10.1016/j.nano.2013.01.009. Epub 2013 Feb 18.

PMID:
23428988
40.

Self-adjuvanting modular virus-like particles for mucosal vaccination against group A streptococcus (GAS).

Rivera-Hernandez T, Hartas J, Wu Y, Chuan YP, Lua LH, Good M, Batzloff MR, Middelberg AP.

Vaccine. 2013 Apr 8;31(15):1950-5. doi: 10.1016/j.vaccine.2013.02.013. Epub 2013 Feb 17.

PMID:
23422147
41.

Long-term antibody memory induced by synthetic peptide vaccination is protective against Streptococcus pyogenes infection and is independent of memory T cell help.

Pandey M, Wykes MN, Hartas J, Good MF, Batzloff MR.

J Immunol. 2013 Mar 15;190(6):2692-701. doi: 10.4049/jimmunol.1202333. Epub 2013 Feb 11.

42.

In vivo efficacy of a chimeric peptide derived from the conserved region of the M protein against group C and G streptococci.

Nordström T, Malcolm J, Magor G, Good MF, Batzloff MR.

Clin Vaccine Immunol. 2012 Dec;19(12):1984-7. doi: 10.1128/CVI.00140-12. Epub 2012 Oct 17.

43.

M-protein-derived conformational peptide epitope vaccine candidate against Group A Streptococcus.

Skwarczynski M, Kamaruzaman KA, Srinivasan S, Zaman M, Lin IC, Batzloff MR, Good MF, Toth I.

Curr Drug Deliv. 2013 Feb;10(1):39-45.

PMID:
22998043
44.

Structure-activity relationship for the development of a self-adjuvanting mucosally active lipopeptide vaccine against Streptococcus pyogenes.

Zaman M, Abdel-Aal AB, Fujita Y, Ziora ZM, Batzloff MR, Good MF, Toth I.

J Med Chem. 2012 Oct 11;55(19):8515-23. doi: 10.1021/jm301074n. Epub 2012 Sep 25.

PMID:
22974133
45.

Vaccination against rheumatic heart disease: a review of current research strategies and challenges.

Pandey M, Batzloff MR, Good MF.

Curr Infect Dis Rep. 2012 Aug;14(4):381-90. doi: 10.1007/s11908-012-0263-7.

PMID:
22729401
46.

Conserved anchorless surface proteins as group A streptococcal vaccine candidates.

Henningham A, Chiarot E, Gillen CM, Cole JN, Rohde M, Fulde M, Ramachandran V, Cork AJ, Hartas J, Magor G, Djordjevic SP, Cordwell SJ, Kobe B, Sriprakash KS, Nizet V, Chhatwal GS, Margarit IY, Batzloff MR, Walker MJ.

J Mol Med (Berl). 2012 Oct;90(10):1197-207. doi: 10.1007/s00109-012-0897-9. Epub 2012 Apr 14.

PMID:
22527883
47.

Immunological evaluation of lipopeptide group A streptococcus (GAS) vaccine: structure-activity relationship.

Zaman M, Abdel-Aal AB, Fujita Y, Phillipps KS, Batzloff MR, Good MF, Toth I.

PLoS One. 2012;7(1):e30146. doi: 10.1371/journal.pone.0030146. Epub 2012 Jan 12.

48.

A microbial platform for rapid and low-cost virus-like particle and capsomere vaccines.

Middelberg AP, Rivera-Hernandez T, Wibowo N, Lua LH, Fan Y, Magor G, Chang C, Chuan YP, Good MF, Batzloff MR.

Vaccine. 2011 Sep 22;29(41):7154-62. doi: 10.1016/j.vaccine.2011.05.075. Epub 2011 Jun 7.

PMID:
21651936
49.

Self-adjuvanting polyacrylic nanoparticulate delivery system for group A streptococcus (GAS) vaccine.

Zaman M, Skwarczynski M, Malcolm JM, Urbani CN, Jia Z, Batzloff MR, Good MF, Monteiro MJ, Toth I.

Nanomedicine. 2011 Apr;7(2):168-73. doi: 10.1016/j.nano.2010.10.002. Epub 2010 Oct 27.

PMID:
21034860
50.

Design of three-component vaccines against group A streptococcal infections: importance of spatial arrangement of vaccine components.

Abdel-Aal AB, Zaman M, Fujita Y, Batzloff MR, Good MF, Toth I.

J Med Chem. 2010 Nov 25;53(22):8041-6. doi: 10.1021/jm1007787. Epub 2010 Oct 28.

PMID:
21028828

Supplemental Content

Loading ...
Support Center